Tracers / [131I]ICF01012

[131I]ICF01012

Also written as [I-131]ICF01012

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: phase I clinical trial (first-in-human)
Syntheses indexed: 3

Melanoma

What it is

Compound class: Benzamide-based melanin-targeting radioligand
Target / mechanism: Binds melanin in pigmented melanoma cells PMID 31421458
Clinical application: Targeted radionuclide therapy for metastatic pigmented melanoma PMID 35428211
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
AllinOne (AiO) Trasis	—	—	—	over 95%	—	35428211 2022 BMC Cancer the synthesis is carried out entirely on an AIO® synthesizer (TRASIS)
—	—	—	—	—	ICF01012	33804655 2021 Cancers (Basel)
—	—	—	—	—	—	31421458 2019 Transl Oncol

Need this precursor?We can point you to suppliers for [131I]ICF01012, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 35428211: 'This study is a first-in-human trial evaluating the [131I]ICF01012 TRT in metastatic malignant melanomas'.